Island Pharmaceuticals (ASX:ILA) appointed US biodefense executive Mark Herzog as senior global health security adviser ahead of the start of its Animal Rule studies for galidesivir in Marburg virus disease, according to a Tuesday Australian bourse filing.
Marburg virus disease, formerly known as Marburg haemorrhagic fever, is a fatal illness caused by the Marburg virus, according to the World Health Organization website.
The company said it is on track to begin planned dose optimization studies in the September quarter, adding that it remains in advanced negotiations with US-based BSL-4 biocontainment facilities regarding the execution of its planned two-stage development pathway.
Island Pharmaceuticals' shares dropped 6% in recent trading on Tuesday.